Invaryant and Cardiex Partner to Expand RPM During Clinical Trials

Health tech firm CardieX’s subsidiary, ATCOR, a medical technology company, has announced a partnership with AI-enabled health tech company Invaryant to conduct joint clinical research on maternal health and cardiovascular disease.  

Invaryant's health platform will integrate digital vascular biomarkers gathered from ATCOR's SphygmoCor arterial technology, which measures the central aortic pressure waveform, to allow for closer patient monitoring of risk factors associated with hypertensive disorders in early 2023. 

Invaryant will also utilize the CONNEQT Pulse, which measures central blood pressure, to obtain multiple arterial health indicators. 

Health analytics platform CONNEQT is another subsidiary of CardieX. 

"It's exciting to see patient-driven technologies expand and enhance decentralized clinical trial outcomes. The ATCOR and Invaryant partnership will integrate the best in personalized vascular biometric monitoring with Inara's advanced AI and machine learning [Invaryant's AI bot platform] to help educate patients about their vascular health and improve patient-reported outcomes. I'm excited to leverage our combined technologies for the best patient experience and access to the most meaningful data," Craig Cooper, group CEO of the CardieX companies, said in a statement. 

Earlier in 2022, CardieX and Mobvoi, an AI-enabled wearable company, launched TicWatch GTH Pro, a consumer smartwatch that utilizes the SphygmoCor technology to monitor heart health.

Join the HealthXL Webinar on ‘Retail Healthcare: Current and Future Opportunities for Digital Health’ on 26th January. Click here to Request to Join. 

Click here to read the original news story.